Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 2,084 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Plaque Psoriasis
Interventions: TAK-279; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 2,099 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 74
States / cities: Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 62 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: FWD1509 MsOH; Drug
Lead sponsor: Forward Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Canton, Ohio • Houston, Texas

Conditions: Gouty Arthritis
Interventions: Canakinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cancers, Pain, Lower Back Pain
Interventions: Oxymorphone ER; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Atrial Fibrillation, Stroke
Interventions: dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 12
States / cities: La Mesa, California • Pensacola, Florida • Port Charlotte, Florida + 9 more

Conditions: Acute Gouty Arthritis Flares
Interventions: ACZ885, Triamcinolone acetonide 40 mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Anniston, Alabama • Mobile, Alabama • Norwalk, California + 28 more

Conditions: Hypercholesterolemia
Interventions: Enlicitide Decanoate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 52
States / cities: Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 48 more

Conditions: Recurrent Pericarditis
Interventions: Rilonacept, Placebo; Drug
Lead sponsor: Kiniksa Pharmaceuticals (UK), Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 9 more

Conditions: Glabellar Frown Lines
Interventions: Botulinum Toxin A, Placebo; Drug
Lead sponsor: Croma-Pharma GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bipolar I Disorder
Interventions: Licarbazepine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Cerritos, California

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: Adhansia XR; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Little Rock, Arkansas • Colorado Springs, Colorado • Jacksonville, Florida + 12 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, SOC; Biological · Other
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Tucson, Arizona • Boston, Massachusetts • Rochester, Minnesota + 1 more

Conditions: Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions: Collagenase Clostridium Histolyticum; Biological
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Beverly Hills, California • Murrieta, California • Oceanside, California + 11 more

Conditions: Diabetes Mellitus, Type 1
Interventions: insulin icodec, insulin degludec, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 42
States / cities: Concord, California • Escondido, California • Fresno, California + 36 more

Conditions: Migraine
Interventions: Lasmiditan, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 10 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Quadrivalent influenza vaccine, Ofatumumab, iDMT; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Phoenix, Arizona • Hollywood, Florida • St Louis, Missouri

Conditions: Atopic Dermatitis Eczema
Interventions: AO+Mist, Placebo; Other
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ulcerative Colitis
Interventions: Tulisokibart, Companion Diagnostic (CDx) Testing, Placebo; Drug · Device · Other
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 29
States / cities: Mobile, Alabama • Phoenix, Arizona • Sun City, Arizona + 24 more

Conditions: Tobacco Use Disorder, Tobacco Dependence, Smoking
Interventions: Anatabloc(TM), CigRx(R); Dietary Supplement
Lead sponsor: Rock Creek Pharmaceuticals, Inc.; Industry
Eligibility: 23 Years to 72 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Martinsburg, West Virginia

Conditions: Ankylosing Spondylitis
Interventions: AIN457A; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 5 more

Conditions: Knee Osteoarthritis
Interventions: Hymovis Intra-articular Injection, Phosphate Buffered Saline Injection; Device · Procedure
Lead sponsor: Fidia Farmaceutici s.p.a.; Industry
Eligibility: 40 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 28 more

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions: Losmapimod; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 12
States / cities: Irvine, California • Los Angeles, California • Gainesville, Florida + 9 more

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 1,153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 160
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more

Conditions: Recurrent Pericarditis
Interventions: KPL-914; Drug
Lead sponsor: Kiniksa Pharmaceuticals (UK), Ltd.; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Washington D.C., District of Columbia • DeLand, Florida • Jacksonville, Florida + 11 more

Search by objective public record fields.

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis

Hymovis™ Versus Placebo in Knee Osteoarthritis

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

A Pilot Study of KPL-914 in Recurrent Pericarditis